Skip to main content
. 2014 Jan 24;13:11. doi: 10.1186/1476-4598-13-11

Figure 4.

Figure 4

Analysis of MLH1 deficient Lynch syndrome and MLH1 proficient sporadic CRC. Immunhistochemistry demonstrated loss of (A) MLH1 as well as (B) significant reduction of SPTAN1 in Lynch syndrome CRC tissue whereas MLH1 and SPTAN1 was strong expressed (C and D) in the sporadic CRC, respectively. Magnification 100×. In addition, Western blot analysis (E) of MLH1 deficient fresh tumor tissue (lane 1) in comparison to normal tissue (lane 2) of MLH1 promotermethylated sporadic CRC showed a clear decrease of SPTAN1 in the MLH1 deficient tumor tissue (lane 1, middle panel). All MLH1 deficient species showed reduction of SPTAN1 expression (see Table 1).